Protection Against Parkinson’s Disease Progression: Clinical Experience
Authors:
- Peter A. LeWittPLPeter A. LeWitt
- Danette C. TaylorDTDanette C. Taylor
- 1 April 2008
- journal article
- review article
- Published by Elsevier in Neurotherapeutics
- Vol. 5 (2) , 210-225
Abstract
No abstract availableKeywords
This publication has 113 references indexed in Scilit:
- Assessment of the progression of Parkinson's disease: a metabolic network approachThe Lancet Neurology, 2007
- Parkin Gene Therapy for α-Synucleinopathy: A Rat Model of Parkinson's DiseaseHuman Gene Therapy, 2005
- Oxidative stress in Parkinson's diseaseAnnals of Neurology, 2003
- A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18 F-dopa PET studyJournal of Neural Transmission, 2002
- The effect of deprenyl washout in patients with long-standing Parkinson's diseaseJournal of Neural Transmission, 2002
- Are Dopamine Receptor Agonists Neuroprotective in Parkinson??s Disease?Drugs & Aging, 2001
- Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamineJournal of Neural Transmission, 2000
- Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexoleJournal of Neural Transmission, 1997
- AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITYBrain, 1991
- Effect of Deprenyl on the Progression of Disability in Early Parkinson's DiseaseNew England Journal of Medicine, 1989